University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
US pharma major Eli Lilly recently announced top-line results of tirzepatide from its SURMOUNT-1 Phase III clinical trial, which has stirred up the outlook for the pharmacological weight management market. 13 May 2022
The European pharma industry has released a new report offering recommendations to improve outcomes for people living with a cardiovascular disease (CVD) in the region. 13 May 2022
The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). 13 May 2022
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
For researchers unaffiliated with an academic library, it can be hard to find, organize, and share scientific papers. Can a new tool address this gap? 12 May 2022
The World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the USA’s National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19. 12 May 2022
Switzerland’s EffRx Pharmaceuticals, Slovenia’s Medis, Russia’s Orpharm, Brazil’s OrphanDC, and Dubai-based Vector Pharma, announced today the newly-formed World Orphan Drug Alliance (WODA). 12 May 2022
In line with most analysts’ expectations, Germany’s Merck KGaA has reported group sales of 5.2 billion euros ($5.4 billion) for the first quarter, an increase of 12.2%. 12 May 2022
Tokyo’s Taiho Pharmaceutical, a business of Japanese drug major Otsuka Pharmaceutical, has agreed to buy part of Cullinan Oncology, thereby regaining rights to a candidate it out-licensed in 2019. 12 May 2022
Netherlands-based Qiagen has signed agreements to acquire a 96% majority ownership stake in Blirt SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. 12 May 2022
Shares in Miami-based Veru were 4% higher at lunchtime Wednesday on the back of some good news from the US Food and Drug Administration (FDA). 11 May 2022
Japanese ophthalmology specialist Santen Pharmaceutical has received approval of Verkazia (ciclosporin eye drops) from the National Medical Products Administration (NMPA) in China through its Chinese legal entity for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged 4 years and above. 11 May 2022
The US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) has announced the launch of the new Accelerating Rare disease Cures (ARC) Program. 11 May 2022
Shares of Denmark-based CNS specialist Lundbeck were up 7% at 161.30 Danish kroner in early afternoon trading, after it released a strong set of first-quarter 2022 financials. 11 May 2022
The USA’s medicine cost watchdog the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of the following outpatient treatments for COVID-19: 10 May 2022
Italian drugmaker Recordati saw its shares gain 2.1% to 42.31 euros by early afternoon, as the company released first-quarter 2022 financial results. 10 May 2022
German pharma major Bayer has reported a strong start to the year, with group sales up 14.3% at 14.6 billion euros ($15.4 billion), including 4.6 billion euros from pharmaceuticals, a 5.9% increase. 10 May 2022
The US Food and Drug Administration yesterday announced the availability of a draft guidance for industry, Benefit-Risk Considerations for Product Quality Assessments. 10 May 2022